Adverse events following CART-ddBCMA infusion
Event . | Cohort . | ||
|---|---|---|---|
| 100 × 106 (N = 6) n (%) . | 300 × 106 (N = 6) n (%) . | Total (N = 12) n (%) . | |
| Subjects with at least 1 ≥grade 3 AE, % | 6 (100) | 6 (100) | 12 (100) |
| Neutropenia, % | 6 (100) | 5 (83.3) | 11 (91.7) |
| Anemia, % | 5 (83.3) | 5 (83.3) | 10 (83.3) |
| Lymphocytopenia, % | 5 (83.3) | 3 (50.0) | 8 (66.7) |
| Thrombocytopenia, % | 2 (33.3) | 4 (66.7) | 6 (50.0) |
| Leukopenia, % | 3 (50.0) | 2 (33.3) | 5 (41.7) |
| Hyponatremia, % | 2 (33.3) | 0 | 2 (16.7) |
| Febrile neutropenia, % | 3 (50.0) | 1 (16.7) | 4 (33.3) |
| Hypertension, % | 2 (33.3) | 1 (16.7) | 3 (25.0) |
Event . | Cohort . | ||
|---|---|---|---|
| 100 × 106 (N = 6) n (%) . | 300 × 106 (N = 6) n (%) . | Total (N = 12) n (%) . | |
| Subjects with at least 1 ≥grade 3 AE, % | 6 (100) | 6 (100) | 12 (100) |
| Neutropenia, % | 6 (100) | 5 (83.3) | 11 (91.7) |
| Anemia, % | 5 (83.3) | 5 (83.3) | 10 (83.3) |
| Lymphocytopenia, % | 5 (83.3) | 3 (50.0) | 8 (66.7) |
| Thrombocytopenia, % | 2 (33.3) | 4 (66.7) | 6 (50.0) |
| Leukopenia, % | 3 (50.0) | 2 (33.3) | 5 (41.7) |
| Hyponatremia, % | 2 (33.3) | 0 | 2 (16.7) |
| Febrile neutropenia, % | 3 (50.0) | 1 (16.7) | 4 (33.3) |
| Hypertension, % | 2 (33.3) | 1 (16.7) | 3 (25.0) |